T/myeloid MPAL with biallelic CEBPA mutations No … ← Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial T/myeloid MPAL with biallelic CEBPA mutations →